Datopotamab Deruxtecan, often abbreviated as DATO, represents an significant advancement in targeted cancer therapy. This new antibody-drug conjugate joins an monoclonal antigen specifically targeting HER-2 expressing https://www.targetmol.com/compound/datopotamab